Novartis now top dog in skin drugs with $1.5B Fougera buy

Another day, another deal. Novartis ($NVS) has snapped up Fougera Pharmaceuticals, a U.S.-based maker of generic skin treatments, for $1.5 billion. The buyout will make the Swiss company's generics un…
Read the full story: News